ZORYVE cream 0.15% by Arcutis showed consistent improvements in atopic dermatitis across skin types

From Nasdaq: 2024-09-25 01:44:21

Arcutis Biotherapeutics Inc. announced that ZORYVE cream 0.15% showed consistent improvements in atopic dermatitis across different races and skin types. Patients also experienced a reduction in itch. The incidence of adverse events was low and similar between ZORYVE and vehicle-treated patients, with favorable local tolerability. Common side effects included headache and nausea. ZORYVE cream is approved for mild to moderate atopic dermatitis and plaque psoriasis in patients 6 years and older. For more health news, visit rttnews.com.



Read more at Nasdaq: Arcutis : ZORYVE Cream 0.15% Improves Atopic Dermatitis Across Skin Types In Phase 3 Trials